Obesity‐related glomerulopathy: How it happens and future perspectives
Diabetic Medicine · 2025-06 · 42 (6)
DOI: 10.1111/dme.70042 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetic Medicine, online erschienen am 14.04.2025. Verfasst von Jian-Wen Samuel Lee-Boey und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia. Hauptthemen laut MEDLINE: Obesity, Diabetic Nephropathies. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 67 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: UK Medical Research Council, National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM), NIHR Leicester Biomedical Research Centre (BRC).
Abstract (Originalsprache)
Obesity‐related glomerulopathy (ORG) is an emerging complication of excess adiposity. Its incidence rises alongside the obesity pandemic. Up to 40% of individuals can be affected by ORG, irrespective of the status of glomerular filtration rate and albuminuria. ORG is a distinct histological diagnosis based on kidney biopsy, showing classical features of an enlarged glomerulus with and without focal segmental glomerulosclerosis in the perihilar region seen with all categories of obesity. About 10% of individuals with ORG may progress to end‐stage kidney disease. The invasive nature of kidney biopsy highlights the need for non‐invasive biomarkers for improved screening, diagnosis and risk prediction of ORG. These biomarkers may narrow the gaps in the management of ORG by improving: (1) screening, diagnosis and differentiation of ORG from non‐ORG conditions; (2) risk prediction and stratification of individuals at risk of progression to end‐stage kidney disease including the detection of trajectories of progression; (3) monitoring of treatment safety and effectiveness and (4) development of novel therapeutic targets. In the present review, we discussed the pathophysiology, emerging biomarkers (such as kidney injury molecule‐1 [KIM‐1], uromodulin, klotho, circulating microRNA‐21 [miR‐21]) and future treatment strategies (metabolic surgery, sodium‐glucose cotransporter‐2 inhibitors, incretin‐based therapy and non‐steroidal mineralocorticoid antagonists) of ORG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Faculty of Medicine, Universiti Malaya, Kuala Lumpur, Malaysia.
- Diabetes Research Centre, University of Leicester, Leicester General Hospital, Leicester, UK.
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
- School of Population Health, Royal College of Surgeons of Ireland, Dublin, Ireland.
- Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, SAR, China.
- Asia Diabetes Foundation, Hong Kong, SAR, China.
ORCID-Profile: Jian-Wen Samuel Lee-Boey, Kamlesh Khunti, Lee-Ling Lim
Förderung
- UK Medical Research Council
- National Institute for Health Research (NIHR) Applied Research Collaboration East Midlands (ARC EM)
- NIHR Leicester Biomedical Research Centre (BRC)
- Medical Research Council
- National Institute for Health and Care Research
Zitieren
APA
Lee-Boey, J. S., Tan, J. K., Lim, Z. F., Zaccardi, F., Khunti, K., Ezzati, M., Gregg, E. W., & Lim, L. L. (2025). Obesity‐related glomerulopathy: How it happens and future perspectives. Diabetic Medicine, 42(6). https://doi.org/10.1111/dme.70042
Vancouver
Lee-Boey JS, Tan JK, Lim ZF, Zaccardi F, Khunti K, Ezzati M, et al. Obesity‐related glomerulopathy: How it happens and future perspectives. Diabetic Medicine. 2025;42(6). doi:10.1111/dme.70042
BibTeX
@article{LeeBoey2025,
author = {Lee-Boey, Jian-Wen Samuel and Tan, Jia-Kai and Lim, Zhan-Foong and Zaccardi, Francesco and Khunti, Kamlesh and Ezzati, Majid and Gregg, Edward W and Lim, Lee-Ling},
title = {Obesity‐related glomerulopathy: How it happens and future perspectives},
journal = {Diabetic Medicine},
year = {2025},
volume = {42},
number = {6},
doi = {10.1111/dme.70042}
}
EUVIMED